Digital Biomarkers for Early Neurodevelopmental Risk Stratification

This direction is merged into another direction: diagnostic latency (early intervention window). Its last version stays readable and citable here.

Version 1 of 121 papers21 conceptsfrozen 2026-10-04

The clinical diagnosis of neurodevelopmental conditions like Autism Spectrum Disorder (ASD), ADHD, and Cerebral Palsy often follows a "wait-to-fail" model. Because traditional diagnosis relies on observable behavioral milestones—such as speech delays or social deficits—children are frequently not identified until ages three to five. By this time, the peak window of neuroplasticity, during which early intervention is most transformative, has already begun to close.

To bridge this gap, researchers are developing digital biomarkers: objective, automated measures of behavior and physiology that can be captured via standard mobile devices or existing medical records. The goal is to move from subjective clinical observation to scalable, high-frequency risk stratification.

Capturing the "Behavioral Phenotype" via Computer Vision

The most visible facet of this research involves using computer vision to quantify subtle behavioral cues that are difficult for the human eye to measure consistently. Instead of relying on a clinician’s intuition during a brief visit, researchers like Jordan Hashemi and Mariano Tepper have developed tools to automate the analysis of visual attention and motor patterns in infants (Computer vision tools for the non-invasive assessment of autism-related behavioral markers).

This approach works by decomposing complex social interactions into discrete, measurable data points:

By moving these tools onto mobile platforms, as seen in the "Autism & Beyond" app developed by Helen L. Egger and Géraldine Dawson, screening can happen "in the wild"—at home, where children are most comfortable (Automatic emotion and attention analysis of young children at home: a ResearchKit autism feasibility study).

Mining the "Shadow" of Clinical Data

A second major direction focuses on "digital biomarkers" hidden within existing Electronic Health Records (EHR). Even before a behavioral diagnosis is considered, children with neurodevelopmental risks often leave a trail of distinct medical signatures.

Ishanu Chattopadhyay and colleagues developed the Autism Co-morbid Risk Score (ACoR), which analyzes patterns of common comorbidities—such as immune system issues or sleep disorders—to identify high-risk children as early as age two (Reduced False Positives in Autism Screening Via Digital Bio-markers Inferred from Deep Co-morbidity Patterns). Similarly, Matthew M. Engelhard found that children later diagnosed with ASD or ADHD show significantly higher healthcare utilization rates before their first birthday (Health system utilization before age 1 among children later diagnosed with autism or ADHD).

This data-driven approach extends even further back to maternal health. Yi Guo and Elizabeth Shenkman showed that linking a mother’s EHR data from pregnancy with her child’s early records can improve predictive accuracy, particularly for girls who are often overlooked by traditional screening (Machine Learning Prediction of Autism Spectrum Disorder Through Linking Mothers’ and Children’s Electronic Health Record Data).

Physiological and Neural Precursors

Beyond behavior and records, researchers are looking for "hard" biological markers that precede symptoms.

Why This Works: From Observation to Prediction

The intuition behind this research is that neurodevelopmental conditions are not "on/off" switches that flip at age three; they are trajectories that begin in utero. By using machine learning to aggregate thousands of subtle signals—from the way an infant moves their hands (Kevin D. McCay) to the way they look at a screen (Xuejun Kong)—these systems can detect the "statistical shadow" of a disorder long before it manifests as a clinical delay.

This shift from diagnostic observation to risk stratification allows the medical system to prioritize the children most in need, potentially slashing the months-long waiting lists for specialist evaluations described by Jianbo Yuan and Jiebo Luo (Autism spectrum disorder detection from semi-structured and unstructured medical data).

Papers in this version

History & citationVersion 1 · 2026-10-04

Merged into another direction · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_digital_biomarkers_for_early_neurodevelo_0b2e12e7,
  title = {Digital Biomarkers for Early Neurodevelopmental Risk Stratification},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/digital-biomarkers-for-early-neurodevelopmental-risk-stratification/rdr_0b2e12e7e95b4e38891e603b88350db0},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-22},
}

This exact version (version 1, frozen text):

@misc{lacuna_digital_biomarkers_for_early_neurodevelo_0b2e12e7_v1,
  title = {Digital Biomarkers for Early Neurodevelopmental Risk Stratification},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/digital-biomarkers-for-early-neurodevelopmental-risk-stratification/rdr_0b2e12e7e95b4e38891e603b88350db0/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-22},
}